Growth factors such as (e.g., VEGF, platelet-derived growth factor [PDGF] bind to a receptor tyrosine kinase (RTK) on the cell membrane, causing autophosphorylation of the receptor, thus creating docking sites for intracellular signaling proteins
Not only could that make them less inclined to approve the medication, they may also not have the knowledge and experience to guide your use
Two to three strength-training sessions per week is the evidence-based minimum for meaningful muscle preservation during GLP-1 therapy
The tirzepatide removal, without the due process of proper federal notice, at a time when they acknowledge that shortages still exist, is the definition of arbitrary and capricious, said Lee H

We discuss: Medicare Bridge Program eligibility requirements Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates BMI and comorbidity qualifications Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access How Medicare patients can obtain GLP-1 medications Why obesity is finally being treated as a chronic disease The future of obesity medicine and Medicare coverage Concerns about access to care vs access to medication Muscle loss, nutrition, strength training, and healthy weight loss The Treat and Reduce Obesity Act (TROA) This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care
How do GLP-1 medications like Ozempic work